Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy in marginalized HIV-1 patients
NCT04132674Phase 4Unknown
- Sponsor
- Vancouver Infectious Diseases Centre
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Vancouver Infectious Diseases Centre. Primary endpoint: Proportion of subjects virally suppressed at 48 weeks. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04132674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132674.